SG11202000823WA - Thiazolopyridine derivatives as adenosine receptor antagonists - Google Patents

Thiazolopyridine derivatives as adenosine receptor antagonists

Info

Publication number
SG11202000823WA
SG11202000823WA SG11202000823WA SG11202000823WA SG11202000823WA SG 11202000823W A SG11202000823W A SG 11202000823WA SG 11202000823W A SG11202000823W A SG 11202000823WA SG 11202000823W A SG11202000823W A SG 11202000823WA SG 11202000823W A SG11202000823W A SG 11202000823WA
Authority
SG
Singapore
Prior art keywords
receptor antagonists
adenosine receptor
thiazolopyridine derivatives
thiazolopyridine
derivatives
Prior art date
Application number
SG11202000823WA
Inventor
Eva-Maria Tanzer
Kai Schiemann
Markus Klein
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of SG11202000823WA publication Critical patent/SG11202000823WA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/429Thiazoles condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
SG11202000823WA 2017-08-01 2018-07-02 Thiazolopyridine derivatives as adenosine receptor antagonists SG11202000823WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17184272 2017-08-01
PCT/EP2018/067797 WO2019025099A1 (en) 2017-08-01 2018-07-02 Thiazolopyridine derivatives as adenosine receptor antagonists

Publications (1)

Publication Number Publication Date
SG11202000823WA true SG11202000823WA (en) 2020-02-27

Family

ID=59506176

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202000823WA SG11202000823WA (en) 2017-08-01 2018-07-02 Thiazolopyridine derivatives as adenosine receptor antagonists

Country Status (23)

Country Link
US (1) US11186592B2 (en)
EP (1) EP3661941B1 (en)
JP (1) JP7336434B2 (en)
KR (1) KR20200035439A (en)
CN (1) CN110997681B (en)
AU (1) AU2018309265B2 (en)
BR (1) BR112020001978A2 (en)
CA (1) CA3071575A1 (en)
DK (1) DK3661941T3 (en)
ES (1) ES2940407T3 (en)
FI (1) FI3661941T3 (en)
HR (1) HRP20230251T1 (en)
HU (1) HUE061308T2 (en)
IL (1) IL272284B2 (en)
LT (1) LT3661941T (en)
PL (1) PL3661941T3 (en)
PT (1) PT3661941T (en)
RS (1) RS64035B1 (en)
SG (1) SG11202000823WA (en)
SI (1) SI3661941T1 (en)
TW (1) TW201920201A (en)
WO (1) WO2019025099A1 (en)
ZA (1) ZA202001295B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR117844A1 (en) * 2019-01-22 2021-09-01 Merck Patent Gmbh THIAZOLOPYRIDINE DERIVATIVES AS ANTAGONISTS OF THE ADENOSINE RECEPTOR
CN112174943A (en) * 2019-07-03 2021-01-05 四川大学 Application of indole-2-ketone compound in preparation of oral bacteria prevention and treatment product
CA3220380A1 (en) 2021-06-07 2022-12-15 Rinat ZAYNAGETDINOV Combination treatment of cancer
WO2024028273A1 (en) 2022-08-02 2024-02-08 Merck Patent Gmbh Novel crystalline forms of (s)-7-oxa-2-aza-spiro[4.5]decane-2-carboxylic acid [7-(3,6-dihydro-2h-pyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-amide and co-crystal forms thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4125828A (en) 1972-08-04 1978-11-14 Med-El Inc. Method and apparatus for automated classification and analysis of cells
US4207554A (en) 1972-08-04 1980-06-10 Med-El Inc. Method and apparatus for automated classification and analysis of cells
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
KR19990082463A (en) 1996-02-13 1999-11-25 돈 리사 로얄 Quinazolin derivatives as vascular endothelial growth factor inhibitors
WO1997032856A1 (en) 1996-03-05 1997-09-12 Zeneca Limited 4-anilinoquinazoline derivatives
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
WO1999035147A1 (en) 1998-01-05 1999-07-15 Eisai Co., Ltd. Purine derivatives and adenosine a2 receptor antagonists serving as preventives/remedies for diabetes
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
ATE303387T1 (en) 1999-07-02 2005-09-15 Eisai Co Ltd CONDENSED IMIDAZOLE DERIVATIVES AND DRUGS FOR DIABETES MELLITUS
EP1289952A1 (en) 2000-05-31 2003-03-12 AstraZeneca AB Indole derivatives with vascular damaging activity
YU96502A (en) * 2000-06-21 2006-01-16 F. Hoffmann-La Roche Ag. Benzothiazole derivatives
SK52003A3 (en) 2000-07-07 2003-07-01 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors, method for their preparation and pharmaceutical composition comprising the same
AU6623301A (en) 2000-07-07 2002-01-21 Angiogene Pharm Ltd Colchinol derivatives as vascular damaging agents
WO2004089942A2 (en) 2001-10-02 2004-10-21 Acadia Pharmaceuticals Inc. Benzimidazolidinone derivatives as muscarinic agents
CA2470104C (en) 2001-12-12 2015-01-27 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Methods for using extracellular adenosine inhibitors and adenosine receptor inhibitors to enhance immune response and inflammation
US6713499B2 (en) * 2001-12-12 2004-03-30 Hoffman-La Roche Inc. 7-Amino-benzothiazole derivatives
US20080070932A1 (en) 2003-04-09 2008-03-20 Chi Vu Triazolo[ 1,5-A] Pyrimidines And Pyrazolo[ 1,5-A] Pyrimidines And Methods Of Making And Using The Same
US6872833B2 (en) * 2003-04-14 2005-03-29 Hoffmann-La Roche Inc. Adenosine receptor ligands
EP1636223B1 (en) * 2003-05-19 2008-03-19 F. Hoffman-la Roche AG Benzothiazole derivatives as adenosine receptor ligands
BRPI0414266A (en) * 2003-09-19 2006-11-07 Hoffmann La Roche thiazolopyridine derivatives as adenosine receptor ligands
CA2574193C (en) 2004-07-22 2013-03-05 F. Hoffmann-La Roche Ag Benzothiazole derivatives as adenosine receptor ligands
KR101077295B1 (en) * 2006-05-18 2011-10-26 에프. 호프만-라 로슈 아게 Thiazolo-pyramidine/pyridine urea derivatives as adenosine a2b receptor antagonists
US8168785B2 (en) * 2009-06-17 2012-05-01 Biotie Therapies, Inc. Benzothiazole derivatives
GB201416754D0 (en) 2014-09-23 2014-11-05 Mission Therapeutics Ltd Novel compounds

Also Published As

Publication number Publication date
PT3661941T (en) 2023-03-16
CN110997681B (en) 2022-11-15
WO2019025099A1 (en) 2019-02-07
TW201920201A (en) 2019-06-01
US11186592B2 (en) 2021-11-30
AU2018309265B2 (en) 2022-06-02
HRP20230251T1 (en) 2023-04-14
LT3661941T (en) 2023-04-11
DK3661941T3 (en) 2023-03-13
IL272284A (en) 2020-03-31
RS64035B1 (en) 2023-04-28
JP7336434B2 (en) 2023-08-31
RU2020107737A (en) 2021-09-02
JP2020528922A (en) 2020-10-01
CN110997681A (en) 2020-04-10
RU2020107737A3 (en) 2021-11-23
KR20200035439A (en) 2020-04-03
AU2018309265A1 (en) 2020-03-19
ZA202001295B (en) 2023-09-27
PL3661941T3 (en) 2023-05-08
SI3661941T1 (en) 2023-04-28
BR112020001978A2 (en) 2020-08-18
HUE061308T2 (en) 2023-06-28
FI3661941T3 (en) 2023-03-23
CA3071575A1 (en) 2019-02-07
ES2940407T3 (en) 2023-05-08
US20200181171A1 (en) 2020-06-11
IL272284B2 (en) 2024-01-01
EP3661941A1 (en) 2020-06-10
EP3661941B1 (en) 2022-12-14
IL272284B1 (en) 2023-09-01

Similar Documents

Publication Publication Date Title
IL272056A (en) Heterocyclic compounds as adenosine antagonists
ZA201705092B (en) Substituted nucleoside derivatives useful as anticancer agents
GB201514875D0 (en) Receptor
HK1252163A1 (en) Receptor
SG11202001340VA (en) Quinoxaline derivatives as adenosine receptor antagonists
GB201717974D0 (en) Modified receptors
IL277744A (en) Pyrazolotriazolopyrimidine derivatives as a2a receptor antagonist
SG11202000823WA (en) Thiazolopyridine derivatives as adenosine receptor antagonists
IL285024A (en) Thiazolopyridine derivatives as adenosine receptor antagonists
IL253848B (en) Amide compounds as 5-ht4 receptor agonists
GB201702617D0 (en) Receptor
SG11202104081XA (en) 5-azaindazole derivatives as adenosine receptor antagonists
SG11202001337XA (en) Bezimidazole derivatives as adenosine receptor antagonists
EP3350167A4 (en) Androgen receptor antagonists
LT3652176T (en) Substituted xanthine derivatives
SG11202104078PA (en) 5-azaindazole derivatives as adenosine receptor antagonists
HK1231414A1 (en) 5-ht4 receptor agonist for gastroparesis 5-ht4
EP3388423A4 (en) Nk1 receptor antagonist
ZA202000758B (en) Fluoropiperidine compounds as pure 5-ht6 receptor antagonists
GB201701887D0 (en) Receptor
GB201700926D0 (en) Receptor